Alimera Sciences, Inc. announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately. Mr. Maltz began his career as an audit manager for Deloitte &Touche LLP before joining Sapient Corp., a publicly traded global agency providing strategic business and advertising consulting services where he was the Technical Accounting and SEC Reporting Manager. Most recently he was the Chief Financial Officer with Orgenesis, Inc., a publicly traded global biotech company transforming the processing of cell and gene therapies.

Prior to this he was with Gelesis Holdings, Inc., a publicly traded multi-national commercial stage company focused on advancing first-in-class therapeutics to treat excess weight and other gastric conditions. At Gelesis, Mr. Maltz advanced from Corporate Controller to Vice President of Finance and then to Chief Financial Officer while leading numerous operational and fundraising initiatives. He received his B.S. in business administration - finance from Elon University and is a licensed C.P.A. in the state of Massachusetts.

Mr. Maltz will be taking on the role from Russell Skibsted. Mr. Skibsteds departure is not the result of any disagreement with management concerning the Companys operations or management.